<DOC>
	<DOC>NCT01142050</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety in the treatment of Insulin Resistance of Type 2 Diabetes Mellitus with Bone Marrow Mesenchymal Stem Cells.</brief_summary>
	<brief_title>Stem Cell Therapy for Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>- To evaluate the feasibility and safety of transplantation treatment using umbilical cord mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing insulin injection treatments. - To assess efficacy of transplantation treatment using umbilical cord mesenchymal stem cells in patients with type 2 diabetes mellitus.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Free will taking part in the study and ability to provide written informed consent; 2. Type 2 diabetes mellitus (as guideline WHO, 1999); 3. Age 1875 years old，Male/Female; 4. 19≤Body mass index (BMI)≤30㎏/㎡; 5. Fast blood glucose (FBG)≥7.0 mmol/L, and HbAc1≥7％; 6. Intravenous insulin tolerance test（ITT）indicate patient being insulin resistance; 7. Not pregnant or nursing; 8. Negative pregnancy test; 9. Fertile patients will use effective contraception. 1. Severe concurrent medical condition (e.g., serious heart disease, lung disease, or hematopoietic dysfunction, or liver dysfunction, or kidney dysfunction); 2. Active infection requiring treatment; 3. Unexplained febrile illness; 4. Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stem cells;</keyword>
	<keyword>diabetes mellitus;</keyword>
	<keyword>treatment.</keyword>
</DOC>